AR046458A1 - Composiciones que comprenden compuestos organicos - Google Patents
Composiciones que comprenden compuestos organicosInfo
- Publication number
- AR046458A1 AR046458A1 ARP040104363A ARP040104363A AR046458A1 AR 046458 A1 AR046458 A1 AR 046458A1 AR P040104363 A ARP040104363 A AR P040104363A AR P040104363 A ARP040104363 A AR P040104363A AR 046458 A1 AR046458 A1 AR 046458A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- phase
- core
- compositions
- organic compounds
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000012071 phase Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012055 enteric layer Substances 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 239000010410 layer Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008385 outer phase Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract 1
- 229960002797 pitavastatin Drugs 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Composiciones farmacéuticas para liberación sostenida que comprenden como ingrediente activo un inhibidor de HMG-CoA reductasa o su sal farmacéuticamente aceptable, comprendiendo dicha composición un núcleo que consiste en una fase interior (interna) y una fase exterior (externa) en donde la fase exterior no comprende un formador de matriz y en donde el núcleo es primero recubierto con una capa de película no funcional y luego con una capa entérica. Método de tratamiento, uso de la composición en la manufactura de un medicamento. Reivindicacion 2: Una composición de acuerdo con la reivindicación 1 en donde la cantidad de pitavastatina o su sal farmacéuticamente aceptable es de aproximadamente 1-50% en peso de la composición del núcleo. Reivindicación 8: Una composición de acuerdo con la reivindicación 7, en donde el formador de matriz es hidroxipropilmetilcelulosa (HPMC).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52537303P | 2003-11-26 | 2003-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046458A1 true AR046458A1 (es) | 2005-12-07 |
Family
ID=34632977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040104363A AR046458A1 (es) | 2003-11-26 | 2004-11-25 | Composiciones que comprenden compuestos organicos |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20070218134A1 (es) |
| EP (1) | EP1689398A2 (es) |
| JP (1) | JP2007512287A (es) |
| KR (1) | KR20060118507A (es) |
| CN (1) | CN1905880A (es) |
| AR (1) | AR046458A1 (es) |
| AU (1) | AU2004292768B2 (es) |
| BR (1) | BRPI0417011A (es) |
| CA (1) | CA2546244A1 (es) |
| MX (1) | MXPA06005953A (es) |
| MY (1) | MY147202A (es) |
| PE (1) | PE20050588A1 (es) |
| RU (1) | RU2006122630A (es) |
| TW (1) | TW200534876A (es) |
| WO (1) | WO2005051346A2 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8048413B2 (en) * | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
| CN102048701B (zh) * | 2010-11-29 | 2013-01-09 | 青岛黄海制药有限责任公司 | 一种匹伐他汀钙肠溶缓释微丸制剂及其制备方法 |
| WO2012141160A1 (ja) * | 2011-04-12 | 2012-10-18 | 沢井製薬株式会社 | ピタバスタチン含有製剤及びその製造方法 |
| WO2012153181A1 (en) * | 2011-05-11 | 2012-11-15 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts |
| EP2959892B1 (en) | 2013-02-22 | 2020-09-09 | Zeria Pharmaceutical Co., Ltd. | Enteric coated tablet |
| CN106687107B (zh) * | 2014-08-13 | 2020-12-25 | 西达-赛奈医疗中心 | 抗产甲烷组合物及其用途 |
| US10736871B2 (en) | 2015-04-01 | 2020-08-11 | Cedars-Sinai Medical Center | Anti-methanogenic lovastatin analogs or derivatives and uses thereof |
| EP3641732A1 (en) * | 2017-06-21 | 2020-04-29 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
| CN111053752A (zh) * | 2018-10-16 | 2020-04-24 | 南京卓康医药科技有限公司 | 一种稳定的匹伐他汀钙的肠溶片及其制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
| US5916595A (en) * | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| CZ20023381A3 (cs) * | 2000-04-12 | 2003-02-12 | Novartis Ag | Kombinované farmaceutické prostředky obsahující antagonistu AT1-receptoru nebo/a inhibitor HMG-CoA reduktázy nebo/a ACE inhibitor |
| CA2359812C (en) * | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| US20030035839A1 (en) * | 2001-05-15 | 2003-02-20 | Peirce Management, Llc | Pharmaceutical composition for both intraoral and oral administration |
| CN100430405C (zh) * | 2001-08-16 | 2008-11-05 | 特瓦制药工业有限公司 | 制备他汀类的钙盐形式的方法 |
| TW200404544A (en) * | 2002-06-17 | 2004-04-01 | Kowa Co | Controlled release pharmaceutical composition |
| GB0217306D0 (en) * | 2002-07-25 | 2002-09-04 | Novartis Ag | Compositions comprising organic compounds |
| SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
-
2004
- 2004-11-24 MY MYPI20044867A patent/MY147202A/en unknown
- 2004-11-25 CN CNA2004800409427A patent/CN1905880A/zh active Pending
- 2004-11-25 JP JP2006540391A patent/JP2007512287A/ja active Pending
- 2004-11-25 EP EP04819224A patent/EP1689398A2/en not_active Withdrawn
- 2004-11-25 RU RU2006122630/15A patent/RU2006122630A/ru not_active Application Discontinuation
- 2004-11-25 AR ARP040104363A patent/AR046458A1/es not_active Application Discontinuation
- 2004-11-25 CA CA002546244A patent/CA2546244A1/en not_active Abandoned
- 2004-11-25 US US10/580,895 patent/US20070218134A1/en not_active Abandoned
- 2004-11-25 BR BRPI0417011-3A patent/BRPI0417011A/pt not_active IP Right Cessation
- 2004-11-25 KR KR1020067010228A patent/KR20060118507A/ko not_active Withdrawn
- 2004-11-25 WO PCT/EP2004/013419 patent/WO2005051346A2/en active Application Filing
- 2004-11-25 MX MXPA06005953A patent/MXPA06005953A/es active IP Right Grant
- 2004-11-25 TW TW093136328A patent/TW200534876A/zh unknown
- 2004-11-25 AU AU2004292768A patent/AU2004292768B2/en not_active Ceased
- 2004-11-26 PE PE2004001169A patent/PE20050588A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004292768B2 (en) | 2009-04-02 |
| AU2004292768A1 (en) | 2005-06-09 |
| TW200534876A (en) | 2005-11-01 |
| PE20050588A1 (es) | 2005-09-05 |
| CA2546244A1 (en) | 2005-06-09 |
| CN1905880A (zh) | 2007-01-31 |
| EP1689398A2 (en) | 2006-08-16 |
| BRPI0417011A (pt) | 2007-02-21 |
| WO2005051346A3 (en) | 2005-08-25 |
| KR20060118507A (ko) | 2006-11-23 |
| JP2007512287A (ja) | 2007-05-17 |
| MY147202A (en) | 2012-11-14 |
| WO2005051346A2 (en) | 2005-06-09 |
| RU2006122630A (ru) | 2008-01-10 |
| US20070218134A1 (en) | 2007-09-20 |
| MXPA06005953A (es) | 2006-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049062A1 (es) | Formulacion de tableta revestida que contiene un inhibidor dpp4, como saxagliptina, y metodo | |
| ES2581985T3 (es) | Sistema terapéutico transdérmico que contiene norelgestromina para la contracepción y el reemplazo hormonal | |
| PE20110057A1 (es) | Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin-2(s)-carbonitrilo de liberacion modificada | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
| CO6501159A2 (es) | Formulaciones farmaceuticas de liberación controlada de nitazoxanida | |
| EA200870154A1 (ru) | Лекарственное средство для местного применения | |
| CL2008000133A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e | |
| PE20130574A1 (es) | Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| GT200900328A (es) | Derivados de bencimidazol | |
| WO2007120868A3 (en) | Bioavailability enhancement of lipophilic drug by use solvent system | |
| CL2008001946A1 (es) | Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas. | |
| ECSP045307A (es) | Combinacion de compuestos organicos | |
| CL2009000241A1 (es) | Compuestos derivados de 5-(2-morfolin-4-il-7h-pirrolo[2,3-d]pirimidin-4-il)pirimidin-2-ilamina; proceso de preparacion; composicion farmaceutica; y uso de los compuestos para tratar o prevenir una enfermedad proliferativa tal como el cancer. | |
| AR046458A1 (es) | Composiciones que comprenden compuestos organicos | |
| MX369117B (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| BRPI0415053B8 (pt) | inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| MX390044B (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia. | |
| PE20081464A1 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
| UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| CR10199A (es) | Derivados de benzimidazol | |
| MX2007008141A (es) | Composicion farmaceutica de sustancias labiles en medio acido. | |
| AR065342A1 (es) | Composiciones farmaceuticas que contienen fumarato de quetiapina | |
| AR064152A1 (es) | Derivados de quinolina antibacterianos,composiciones farmaceuticas que los contienen y metodo de preparacion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |